HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Lymphoma transformation of tumor infiltrating lymphocytes observed in testicular patient‑derived xenograft models.

Abstract
Testicular germ cell tumors (TGCTs) are highly sensitive to cisplatin‑based chemotherapy. Nevertheless, there are metastatic tumors that do not completely respond to front‑line chemotherapy. For these tumors, surgical resection of residual masses is necessary to achieve long‑term disease control. Resected tissues represent valuable clinical material, which may be used for the engraftment into immunocompromised mice to produce patient‑derived xenografts (PDXs). They typically maintain similarities to the parental tumors and therefore serve as more realistic preclinical models. Moreover, a correlation between PDX treatment outcomes and clinical response to chemotherapy has been previously described. The aim of the present study was to establish and characterize TGCT patient‑derived xenografts. These originated from retroperitoneal lymph node metastases infiltrated with TGCTs following previous cisplatin‑based chemotherapy, in order to analyze novel treatment options for cisplatin‑resistant testicular tumors. We generated two testicular patient‑derived xenograft models in SCID beige male mice. Immunohistochemical analyses demonstrated that histological characteristics of the primary tumor were not retained, and transformation into lymphoma, and eventually plasmocytoma, was observed. A potential explanation for the lymphoma transformation observed in PDXs may include tumor‑infiltrating lymphocytes (TILs) in xenografted samples of patients, which are transformed following engraftment into immunodeficient recipient mice. Based on these data, we indicated that lymphomagenesis prevention and terminal differentiation represent new challenges in the establishment of PDX models derived from patients with germ cell tumors.
AuthorsK Kalavska, L Kucerova, S Schmidtova, L Toro, Z Kozovska, L Plank, M Chovanec, P Palacka, D Pindak, D Macak, J Mardiak, M Mego
JournalOncology reports (Oncol Rep) Vol. 40 Issue 6 Pg. 3593-3602 (Dec 2018) ISSN: 1791-2431 [Electronic] Greece
PMID30542732 (Publication Type: Journal Article)
Chemical References
  • Antineoplastic Agents
  • Cisplatin
Topics
  • Adult
  • Animals
  • Antineoplastic Agents (therapeutic use)
  • Cell Transformation, Neoplastic (pathology)
  • Cisplatin (therapeutic use)
  • Humans
  • Lymph Nodes (cytology, pathology)
  • Lymphatic Metastasis
  • Lymphocytes, Tumor-Infiltrating (pathology, transplantation)
  • Lymphoma (pathology)
  • Male
  • Mice
  • Mice, SCID
  • Middle Aged
  • Neoplasms, Germ Cell and Embryonal (pathology, therapy)
  • Testicular Neoplasms (pathology, therapy)
  • Testis (pathology, surgery)
  • Xenograft Model Antitumor Assays (methods)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: